Abbott to Fund Pharmaceutical and Diagnostics Research at the Weizmann Institute of Science
Abbott and Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science (WIS), have signed a three-year agreement in which Abbott will fund research programs at the Weizmann Institute of Science in selected health care fields.
The collaboration will explore scientific opportunities in pharmaceutical discovery, biomarker identification for targeted drug therapies, and advances in diagnostics technologies.
"The Weizmann Institute and Abbott combined have dedicated nearly 200 years to improving lives through innovations in science and technology, and this collaboration is intended to further advance our shared goal," said Edward L. Michael, executive vice president, diagnostics products, Abbott.
Yeda is actively seeking commercial partners to bring technologies of the Weizmann Institute of Science to the marketplace, according to Dr. Ruth Ben Yakar, chief business officer of Yeda. Such partnerships have already yielded dozens of products currently on the market.
"Appreciating the synergism that can rise from strategic collaborations between WIS scientists and global science-based companies such as Abbott, we welcome Abbott to join forces and promote the development of novel pharmaceuticals and advanced diagnostic tools," Dr. Ben Yakar said.
Other news from the department science
